Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated Biologics platform, Co. is developing therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals in the tumor microenvironment. Co.'s product candidates: SNS-101, which is Co.'s monoclonal antibody targeting the immune checkpoint V-domain Ig suppressor of T-cell activation; SNS-102, which is Co.'s monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4; and SNS-103, which is Co.'s monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1. The SNSE stock yearly return is shown above.
The yearly return on the SNSE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SNSE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|